Phase 2 N=27 Prescription Opioid Effects in Abusers Versus Non-Abusers
Opioid-Related Disorders · Substance-Related Disorders
Primary: Breakpoint — 25; 400; 1400; 850 Mouse Clicks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,804 A High School Program for Preventing Prescription Drug Misuse
Prescription Drug Abuse · Substance Abuse · Substance Use (Drugs, Alcohol)
Primary: Prescription Drug Misuse (i.e., Prescription Drug Use Without a Doctor's Prescription) — 1.06; 1.12; 1.11; 1.13 score on a scale
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
N/A N=1,525 The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances
Economics · Fraud · Delivery of Health Care
Primary: 30-day Equivalent Prescribing of Schedule II Controlled Substances — 461.1; 450.0 30-day equivalent prescription fills
N/A N=843 Personalized Health Assessment Related to Medications (Project PHARM)
Feedback, Psychological · Clinical Trial · Substance Abuse
Primary: Change in Past 6 Month Non-Medical Use of Prescription Stimulant Medication Frequency — -2.04; -1.72; -1.03; -.38 Usage days — p=0.03
N/A N=127 Post-op Crowd Sourcing Health Data Via Text-messaging
Orthopedic Surgery · Opioid Use · Acute Injuries Knee
Primary: Number of Opioid Tablets Taken Within 28 Days — 8.05; 11.55 number of pills taken
Phase 2 N=32 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Opioid Abuse
Primary: Subjective Ratings of "Good" Drug Effect — 37; 35; 35 units on a scale
Phase 4 N=60 Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
Abuse Potential
Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 54.30; 90.85; 72.53; 76.05 Score on a 100 mm scale — p=<0.0001
Phase 2 N=49 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Opioid Abuse
Primary: Drug Liking at .5 Hours — 66.0; 74.7; 47.7; 40.9 score on a scale
N/A N=851 Behavioral Insights to Encourage Judicious Prescribing of Opioids
Substance-Related Disorders
Primary: Average Change Over Time in Dispensed Narcotics — 347.65; 350.09; 288.36; 318.60 Morphine milligram equivalents — p=<0.05
N/A N=479 Text Intervention to Facilitate Secure Storage and Disposal of Prescription Opioids
Opioid Misuse
Primary: Percentage of Participants Who Securely Stored Their Opioid Medication During Treatment — 48; 29; 140; 181 Participants — p=0.003
N/A N=235 Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention
Prescription Drug Abuse (Not Dependent) · Intentional Misuse
Primary: Frequency of Prescription Stimulant Diversion — .25; .41; .18; .30 Mean number of times diverted — p=.499
Phase 2 N=16 A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
Opioid Use Disorder
Primary: Positive Subjective Drug Effects (i.e., Drug "Liking"). — 52.1; 57.5; 71.8; 71.5 units on a scale — p=.0001
Phase 2 N=120 Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription
Surgery
Primary: Number of Oxycodone Tablets Used Day 1 — 1.0; 1.0 Oxycodone Tablets — p=.87
Phase 4 N=63 Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
Abuse Potential
Primary: Drug Liking Visual Analog Scale (VAS) — 56.4; 84.9; 59.6; 64.6 score on a scale
Phase 1 N=80 Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Nondependent Opioid Abuse, Episodic
Primary: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours — 88.3; 100.3; 124.7 hrs*mm — p=<0.0001
N/A N=80 Mobile Application for Prescription Drug-Abuse Education (MAPDE)
Prescription Drug Abuse (Not Dependent)
Primary: Current Opioid Misuse Measure (COMM) — .72; .71; .62; .63 score on a scale — p=.72
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
Phase 4 N=304 Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients
Postoperative Pain
Primary: Morphine Milligram Equivalents (MME) of Oxycodone Tablets Taken by Patient — 1089.7; 777.1 Morphine Milligram Equivalents (MME)
Phase 2 N=30 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Opioid Abuse
Primary: Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min) — 11.7; 14.7 score on a scale
Phase 2 N=17 Medication Development for Opioid and Alcohol Abuse
Opioid-use Disorder · Alcohol Use Disorder
Primary: Peak Positive Subjective Responses to Placebo. — 3.3; 2.3 units on a scale
N/A N=299 Primary Care Intervention to Reduce Prescription Opioid Overdoses
Pain · Drug Overdose · Opioid Use Disorders
Primary: Overdose Risk Behaviors — 1.31; 1.21; 1.45; 1.25 score on a scale
N/A N=503 Scenario Tailored Opioid Messaging Program (STOMP) to Improve Risk Understanding in Young Adults
Pain, Postoperative · Medication Adherence · Opioid Use
Primary: Opioid Risk Perception — 31.4; 31.1; 32.8; 30.02 score on a scale — p=.001
Phase 2 N=44 Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Opioid-Related Disorders
Primary: Emax - Maximum Drug Liking — 54.5; 75.0; 72.1; 75.6 score on a scale
N/A N=541 Encouraging Judicious Prescribing of Opioids in Los Angeles County
Substance-Related Disorders
Primary: Average Weekly Change in Morphine Milligram Equivalents (MME) Dispensed — 157.70; 157.81; 103.16; 89.96 Estimated average weekly MME dispensed — p=<0.05
N/A N=555 Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 1: EHR Nudges
Opioid Abuse, Unspecified
Primary: Change in Average Per-clinician Log Total Weekly MME Between Baseline and Intervention for Opioid Naïve and At-Risk Patients (Below 50 MME Daily Dose Rxs) — -0.14; -0.05…